Workflow
Insulet (PODD)
icon
Search documents
Insulet to Announce Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
Businesswire· 2024-01-11 11:00
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2023 on February 22, 2024 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Inves ...
Insulet (PODD) - 2023 Q3 - Earnings Call Transcript
2023-11-03 02:10
Insulet Corporation (NASDAQ:PODD) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Jim Hollingshead - President & Chief Executive Officer Lauren Budden - Interim Chief Financial Officer & Treasurer Conference Call Participants Stephanie Piazzola - Bank of America Jeff Johnson - Baird Matt Taylor - Jefferies Margaret Kaczor - William Blair Caitlin Cronin - Canaccord Genuity Mike Kratky - Leerink Partners Steven Lichtman - Op ...
Insulet (PODD) - 2023 Q3 - Earnings Call Presentation
2023-11-02 23:30
Revenue Performance - Q3'233,4 • Total Company - $432.7, an increase of 27.0%, or 25.1% in constant currency • Total Omnipod - $422.0, an increase of 29.4%, or 27.5% in constant currency • U.S. Omnipod - $320.6, an increase of 34.6% • International Omnipod - $101.4, an increase of 15.2%, or 8.0% in constant currency Other Financial Highlights - Q3'23 • Gross margin of 67.8%, up 1,250 basis points, compared to gross margin of 55.3% in the prior year. Adjusted gross margin4 of 67.3%, up 120 basis points, excl ...
Insulet (PODD) - 2023 Q3 - Quarterly Report
2023-11-02 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33462 ___________________________________________________________ INSULET CORPORATION (Exact name of Registrant as specified in its charter) ___________________________________________ ...
Insulet (PODD) - 2023 Q2 - Earnings Call Transcript
2023-08-09 03:11
Insulet Corporation (NASDAQ:PODD) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Deborah Gordon - VP, IR James Hollingshead - President, CEO & Director Wayde McMillan - EVP, CFO & Treasurer Conference Call Participants Lawrence Biegelsen - Wells Fargo Securities Robert Marcus - JPMorgan Chase & Co. Malgorzata Kaczor - William Blair & Company Joshua Jennings - TD Cowen Danielle Antalffy - UBS Jeffrey Johnson - Robert W. Baird & Co. Michael Sarcone - Jefferies Christopher Pasq ...
Insulet (PODD) - 2023 Q2 - Quarterly Report
2023-08-08 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________ Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33462 ___________________________________________________________ INSULET CORPORATION (Exact name of R ...
Insulet (PODD) - 2023 Q1 - Earnings Call Presentation
2023-05-05 07:16
Christian D Podder Since 2020 Risks and uncertainties include, but are not limited to adverse changes in general economic conditions as well as risks associated with public health crises and pandemics, such as the COVID-19 global pandemic, government actions and restrictive measures implemented in response, supply chain disruptions, delays in clinical trials, and other impacts to the business, our customers, suppliers, and employees; dependence on a principal product platform; ability to maintain and grow o ...
Insulet (PODD) - 2023 Q1 - Earnings Call Transcript
2023-05-05 01:15
Insulet Corporation (NASDAQ:PODD) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Deborah Gordon – President-Investor Relations Jim Hollingshead – President and Chief Executive Officer Wayde McMillan – Executive Vice President and Chief Financial Officer Conference Call Participants Jeff Johnson – Baird Larry Biegelsen – Wells Fargo Securities Robbie Marcus – JPMorgan Joanne Wuensch – Citibank Margaret Kaczor – William Blair Matthew O'Brien – Piper Sandler Travis Steed – Bank of ...
Insulet (PODD) - 2023 Q1 - Quarterly Report
2023-05-04 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33462 ___________________________________________________________ INSULET CORPORATION (Exact name of Registrant as specified in its charter) __________________________________________________________________________________________________ Delaware 04-3523891 (State or Other Jurisdiction of Incorporation or Organization) (I.R ...
Insulet (PODD) - 2022 Q4 - Earnings Call Transcript
2023-02-24 01:59
Insulet Corporation (NASDAQ:PODD) Q4 2022 Results Conference Call February 23, 2023 4:30 PM ET Company Participants Deborah Gordon - VP, IR Jim Hollingshead - President, CEO Wayde McMillan - EVP, CFO Bret Christensen - EVP, CCO Conference Call Participants Robbie Marcus - JP Morgan Larry Biegelsen - Wells Fargo Jeff Johnson - Baird Jayson Bedford - Raymond James Matt Taylor - Jefferies Margaret Kaczor - William Blair Matthew O'Brien - Piper Sandler Chris Pasquale - Nephron Steve Lichtman - Oppenheimer Ope ...